BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kubo H, Murakami T, Matsuyama R, Yabushita Y, Tsuchiya N, Sawada Y, Homma Y, Kumamoto T, Endo I. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. World J Surg 2019;43:3153-60. [PMID: 31549202 DOI: 10.1007/s00268-019-05159-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med 2021;10:5041-50. [PMID: 34250759 DOI: 10.1002/cam4.3870] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hirahara N, Matsubara T, Fujii Y, Kaji S, Kawabata Y, Hyakudomi R, Yamamoto T, Taniura T, Tajima Y. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget 2020;11:2625-35. [PMID: 32676164 DOI: 10.18632/oncotarget.27653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tezuka K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Todaka A, Fukutomi A, Uesaka K. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Pancreatology 2021;21:1451-9. [PMID: 34462214 DOI: 10.1016/j.pan.2021.08.009] [Reference Citation Analysis]
5 Zhang Y, Xu Y, Wang D, Kuang T, Wu W, Xu X, Jin D, Lou W. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Int J Clin Oncol 2021;26:135-44. [PMID: 32959232 DOI: 10.1007/s10147-020-01782-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fu W, Wang K, Yan S, Wang X, Tang B, Chang J, Wang R, Wu T. Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis. Dose Response 2020;18:1559325820942065. [PMID: 32821253 DOI: 10.1177/1559325820942065] [Reference Citation Analysis]
7 Long Y, Zhang Y, Ni L, Yuan X, Liu Y, Tao J, Zhang Y. Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2021;100:e26202. [PMID: 34397999 DOI: 10.1097/MD.0000000000026202] [Reference Citation Analysis]